Cargando…

Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea

STUDY OBJECTIVES: To evaluate long-term safety and maintenance of efficacy of solriamfetol treatment for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea (OSA). METHODS: Participants with narcolepsy or OSA who completed a prior solriamfetol study were eligible. A 2-week titrati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malhotra, Atul, Shapiro, Colin, Pepin, Jean-Louis, Hedner, Jaz, Ahmed, Mansoor, Foldvary-Schaefer, Nancy, Strollo, Patrick J, Mayer, Geert, Sarmiento, Kathleen, Baladi, Michelle, Chandler, Patricia, Lee, Lawrence, Schwab, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Neurological Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315408/ https://www.ncbi.nlm.nih.gov/pubmed/31691827 http://dx.doi.org/10.1093/sleep/zsz220

Ejemplares similares

A randomized study of solriamfetol for excessive sleepiness in narcolepsy
por: Thorpy, Michael J., et al.
Publicado: (2019)

Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment
por: Schweitzer, Paula K., et al.
Publicado: (2021)

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2020)

Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives
por: Abad, Vivien C
Publicado: (2021)

Solriamfetol for the Use of Narcolepsy: A Systematic Review
por: Iturburu, Alisson, et al.
Publicado: (2022)

P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol
por: Thorpy, M, et al.
Publicado: (2021)

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial
por: Videnovic, Aleksandar, et al.
Publicado: (2021)

Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial
por: Vinckenbosch, Frederick, et al.
Publicado: (2022)

Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea
por: Vinckenbosch, Frederick, et al.
Publicado: (2022)

Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Correlates of excessive daytime sleepiness in obstructive sleep apnea: Results from the nationwide SESAR cohort including 34,684 patients
por: Ulander, Martin, et al.
Publicado: (2022)

Determinants of depressive mood in coronary artery disease patients with obstructive sleep apnea and response to continuous positive airway pressure treatment in non‐sleepy and sleepy phenotypes in the RICCADSA cohort
por: Balcan, Baran, et al.
Publicado: (2019)

Pupillometric Assessment of Sleepiness in Narcolepsy
por: Prasad, Bharati, et al.
Publicado: (2011)

A circuit perspective on narcolepsy
por: Adamantidis, A R, et al.
Publicado: (2020)

Larger hypothalamic volume in narcolepsy type 1
por: Juvodden, Hilde T, et al.
Publicado: (2023)

Multidisciplinary care of patients with narcolepsy during coronavirus disease 2019 pandemic in Italy via televisit: the TElemedicine for NARcolepsy feasibility study
por: Pizza, Fabio, et al.
Publicado: (2022)

Management Of Excessive Sleepiness In Patients With Narcolepsy And OSA: Current Challenges And Future Prospects
por: Sahni, Ashima S, et al.
Publicado: (2019)

The use of an online Epworth Sleepiness Scale to assess excessive daytime sleepiness
por: Boyes, Jennifer, et al.
Publicado: (2016)

Multiple treatment comparison in narcolepsy: a network meta-analysis
por: Lehert, Philippe, et al.
Publicado: (2018)

Narcolepsy type 1: what have we learned from genetics?
por: Ollila, Hanna M
Publicado: (2020)

Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility
por: Guevarra, Jay T, et al.
Publicado: (2020)

Lisdexamfetamine to improve excessive daytime sleepiness and weight management in narcolepsy: a case series
por: Aguilar, Ana C., et al.
Publicado: (2019)

Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study
por: Dauvilliers, Yves, et al.
Publicado: (2019)

A Case of A Sleepy Taxi Driver Presenting with Narcolepsy
por: Miskoff, Jeffrey A, et al.
Publicado: (2019)

Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
por: van der Hoeven, Adrienne Elisabeth, et al.
Publicado: (2022)

Pharmacological Interventions for Excessive Daytime Sleepiness in Adults with Narcolepsy: A Systematic Review and Network Meta-Analysis
por: Chien, Po-Yu, et al.
Publicado: (2022)

Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia
por: Mignot, Emmanuel, et al.
Publicado: (2023)

Circadian rhythm of daytime sleepiness in pediatric narcolepsy: A pilot study
por: Ouyang, Hui, et al.
Publicado: (2023)

Experience with the use of modafinil in the treatment of narcolepsy in a outpatient facility specialized in diurnal excessive sleepiness in São Paulo()
por: da Silva Behrens, Nilce Sanny Costa, et al.
Publicado: (2014)

Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials
por: Meskill, Gerard J., et al.
Publicado: (2021)

High nocturnal sleep fragmentation is associated with low T lymphocyte P2Y(11) protein levels in narcolepsy type 1
por: Viste, Rannveig, et al.
Publicado: (2021)

Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
por: Kushida, Clete A, et al.
Publicado: (2021)

Evaluation of the abuse potential of pitolisant, a selective H(3)-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
por: Setnik, Beatrice, et al.
Publicado: (2019)

Examining the impact of excessive daytime sleepiness on utility scores in patients with obstructive sleep apnoea and/or narcolepsy in five European countries
por: Cambron-Mellott, M. Janelle, et al.
Publicado: (2022)

P147 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with obstructive sleep apnoea (OSA) and prescriber rationale for starting treatment with solriamfetol
por: Singh, H, et al.
Publicado: (2021)

The language of sleepiness in obstructive sleep apnea beyond the Epworth
por: Sunwoo, Bernie Y., et al.
Publicado: (2022)

Activity of FAAH-Inhibitor JZP327A in an Experimental Rat Model of Migraine
por: Greco, Rosaria, et al.
Publicado: (2023)

Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
por: Dauvilliers, Yves, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p9pk6usde3acutmg4tsij3bb5k